News

Sanofi plans to axe 2000 jobs
Enlarge image

BusinessFrance

Sanofi plans to axe 2000 jobs

06.07.2012 - The French pharma giant is preparing for a major overhaul of activities in its home market.

Exact numbers are not yet final, but French unions already fear the worst. An estimate of 2,000 jobs lost is “probably close to reality,” said Thierry Bodin, a representative of the CGT union after a meeting with managers today. Europe’s third-biggest drugmaker wants to regroup its research in the Paris region and around Lyon, he said. This might be the end for research in Toulouse, where the blockbuster Plavix blood thinner was developed, and Montpellier. The company also plans to eliminate support functions and cut jobs at its Pasteur vaccine division, Bodin said.

Reuters reports, that Chief Executive Chris Viehbacher told employees that the unspecified number of job cuts, at its Toulouse and Montpellier sites, would be achieved through voluntary redundancies, early retirement and internal mobility. Manufacturing sites in France would not be affected by the project. Jean-Marc Podvin, a spokesman for Sanofi, said in a telephone interview with Bloomberg Businessweek, that no job cut figures were given and all options remain open for Toulouse. Montpellier could become a centre focused on clinical development, he added.

The company’s CEO Viehbacher began to restructure Sanofi in 2009 reducing headcount, closing plants and dropping the least promising projects. As part of a strategic shift, the French drugmaker is aiming at reducing internal research and having other actors, such as small biotechs, academic research to find new molecules and vaccines.

In its course to concentrate on its core competencies, Sanofi has decided to divest its 19.3% stake in the Yves Rocher Group, which operates in a variety of sectors, including cosmetics, home care products and clothing. The Rocher family which already controls most of the company will buy the shares and raise its stake to more than 95%.

http://www.european-biotechnology-news.com/news/news/2012-03/sanofi-plans-to-axe-2000-jobs.html

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Berlin (GER)

XIV. BIONNALE 2016

Aachen

Biomedica 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • RENEURON (UK)3.50 GBP7.69%

FLOP

  • KAROLINSKA (S)8.00 SEK-8.05%
  • NOVACYT (F)1.50 EUR-7.98%
  • UCB (B)62.79 EUR-7.55%

TOP

  • GENMAB (DK)1229.00 DKK26.7%
  • GALAPAGOS (B)50.94 EUR25.8%
  • NICOX (F)10.97 EUR24.7%

FLOP

  • MOBERG PHARMA (S)38.40 SEK-25.4%
  • BIONOR PHARMA (N)0.69 NOK-24.2%
  • BIOCARTIS GROUP NV (B)8.20 EUR-24.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.20 SEK1872.0%
  • NICOX (F)10.97 EUR496.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-87.6%
  • BB BIOTECH (D)44.27 EUR-84.8%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 24.05.2016